27/05/2026 TG Therapeutics announced positive topline results from Phase 3 trial in adults with relapsing form of multiple sclerosis TG Therapeutics announced positive topline results from Phase 3 trial in adults with relapsing form of multiple sclerosis (Ref) TG Therapeutics announced positive topline results from the Phase 3, ENHANCE trial of BRIUMVI® (ublituximab-xiiy; anti-CD20) in adults with relapsing form of multiple sclerosis (RMS). The trial met its primary endpoint,